文献速递免疫规划传染病防控与疫情报告

PICOBOO平台试验:九种新冠疫苗在免疫健全成人中的反应原性

The platform trial in COVID-19 priming and BOOsting (PICOBOO): The reactogenicity of nine licensed COVID-19 vaccines delivered in immunocompetent adults.
PubMed 文献 · Vaccine · 2026-09-05

PICOBOO是一项随机贝叶斯适应性试验,评估九种已上市新冠疫苗在免疫健全成人中作为额外剂次的反应原性。共586名成人接种1049剂,75%报告局部反应、76%报告全身反应,严重反应罕见;NVX-CoV2373局部和全身反应发生率低于mRNA疫苗,但试验未针对疫苗间比较设计,结果仅作描述性解读。

要点

  • 九种新冠疫苗额外剂次接种后局部和全身反应常见但严重反应罕见。
  • NVX-CoV2373局部反应47%、全身反应69%,低于mRNA疫苗。
  • 试验未针对疫苗间比较设计,组间差异应谨慎解读。

核心结论

  • 新冠疫苗额外剂次接种后反应原性事件常见但严重事件罕见。
  • NVX-CoV2373在层内反应原性似低于mRNA疫苗,但试验未针对疫苗间比较设计,结果仅作描述性解读。

研究设计与样本

  • PICOBOO为随机贝叶斯适应性试验,纳入免疫健全的>12岁个体。
  • 586名成人于2022年3月至2024年9月入组,共接种1049剂新冠疫苗。
  • 参与者按年龄队列和基础免疫方案分层,层内随机接种单剂疫苗。
  • 接种后第1-7天记录反应原性事件,第28天收集严重不良事件等,随访至第720天。

主要发现

  • 335剂(57%)随机一次、96剂(16%)两次、97剂(17%)三次、58剂(10%)四次。
  • 786剂(75%)报告至少一种局部反应,798剂(76%)报告至少一种全身反应。
  • 局部反应原性从NVX-CoV2373的47%(110/236)到Moderna的90%(131/145)。
  • 全身反应原性从NVX-CoV2373的69%(162/236)到BNT162b2的85%(121/143)。
  • 疼痛为最常见局部反应,头痛、疲劳、肌痛和寒战为最常见全身反应,严重反应原性事件罕见。

临床怎么用

  • 向成人说明接种新冠疫苗额外剂次后局部和全身反应常见,但严重反应罕见。
  • 解释不同疫苗间反应原性差异时需说明试验未针对疫苗间比较设计,避免因果推断。

局限性

  • 试验未针对疫苗间比较设计,层内疫苗间反应原性差异应作描述性解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PICOBOO is a randomised, Bayesian adaptive trial evaluating immunogenicity and reactogenicity of licensed COVID-19 vaccines in immunocompetent individuals aged >12 years. We present reactogenicity data for nine vaccines administered as additional doses within adult strata based on age cohort and primary vaccination regimen. METHODS: Individuals who had not received a COVID-19 vaccine within three months were eligible. Participants were randomised within each stratum to receive a single vaccine dose. Reactogenicity events were recorded on days 1-7 following vaccination. Serious or medically attended adverse events (AEs), AEs of special interest, and AEs resulting in withdrawal were collected through day 28. Participants were followed until day 720. FINDINGS: A total of 1049 COVID-19 vaccine doses were administered to 586 adults enrolled between March 2022 and September 2024. Of these, 335 (57%), 96 (16%), 97 (17%) and 58 (10%) were randomised one, two, three and four times, respectively. At least one local reaction was reported after 786 (75%) doses and at least one systemic reaction after 798 (76%) doses. Local reactogenicity ranged from 47% (110/236) with NVX-CoV2373 (Nvx) to 90% (131/145) with Moderna, while systemic reactogenicity ranged from 69% (162/236) with Nvx to 85% (121/143) with BNT162b2. Pain was the most common local reaction; headache, fatigue, myalgia, and chills were the most common systemic reactions. Severe reactogenicity events were rare. INTERPRETATION: Reactogenicity events were common but rarely severe. Although reactogenicity appeared less frequent following Nvx than mRNA vaccines within strata, the trial was not powered for between-vaccine comparisons and findings should be interpreted descriptively. FUNDING: Medical Research Future Fund (2014690/2016473) and The Snow Foundation.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. C M, Dymock M, Flanagan KL, et al. The platform trial in COVID-19 priming and BOOsting (PICOBOO): The reactogenicity of nine licensed COVID-19 vaccines delivered in immunocompetent adults. Vaccine. 2026. PMID: 42700749. doi:10.1016/j.vaccine.2026.129034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。